%D8%AA%D9%88%D8%B3%D9%8A%D9%84%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8%D8%AA%D9%88%D8%B3%DB%8C%D9%84%DB%8C%D8%B2%D9%88%D9%85%D8%A8TocilizumabTocilizumabTocilizumabTocilizumab%D8%AA%D9%88%D8%B3%DB%8C%D9%84%DB%8C%D8%B2%D9%88%D9%85%D8%A8TosilitsumabiTocilizumab%D7%98%D7%95%D7%A1%D7%99%D7%9C%D7%99%D7%96%D7%95%D7%9E%D7%91Tocilizumab%E3%83%88%E3%82%B7%E3%83%AA%E3%82%BA%E3%83%9E%E3%83%96%D0%A2%D0%BE%D1%86%D0%B8%D0%BB%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1TocilizumabTocilizumabTocilizumabe%D0%9A%D0%B0%D1%82%D0%B5%D0%B3%D0%BE%D1%80%D0%B8%D1%8F:%D0%A2%D0%BE%D1%86%D0%B8%D0%BB%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1%D0%A2%D0%BE%D1%86%D0%B8%D0%BB%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1TocilizumabTocilizumabTocilizumab%D0%A2%D0%BE%D1%86%D0%B8%D0%BB%D1%96%D0%B7%D1%83%D0%BC%D0%B0%D0%B1TocilizumabQ425154
about
P3781
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related PneumoniaClinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 PneumonitisRandomised Evaluation of COVID-19 Therapy
P4844
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.Tocilizumab for Patients With Giant Cell ArteritisA Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical TransplantationEvaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant CandidatesTocilizumab for KSHV-Associated Multicentric Castleman DiseaseTocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyTocilizumab in Cardiac TransplantationPhase I, Pharmacokinetic, Safety and Tolerability Study in Healthy VolunteersEffects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis PatientsUse of Tocilizumab Drug Levels to Optimize Treatment in RATocilizumab Plus a Short Prednisone Taper for GCATocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationAIDS 347: IL-6 Blockade in Treated HIV InfectionTocilizumab in the Treatment of Refractory Polymyositis and DermatomyositisEffect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid ArthritisEffective Treatment of Severe COVID-19 Patients with TocilizumabThe cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
P921
Q1187697-70c35927-4a64-1787-2ed7-a81560dba879Q1274464-2E08615C-CAB8-4357-B178-CFF75AE1E030Q170990-646F4280-A80F-4ED0-97D7-99C0D32C07F1Q17148432-4D0D5DFE-6507-467E-955B-7BAC86C2136FQ1752891-5E416922-8460-43C7-9692-BC200AC6A021Q1947302-142BD06B-4885-4F9D-89BD-B04C5CE16852Q432462-B1312EF1-4831-4FA9-AFC3-ABA4A97BF286Q707816-DE987E22-E47C-4555-B1D4-070A9B181F26Q84263196-a22242d8-4555-fc2a-05fc-655af11092ae
P2176
Q33527462-3d514d75-46dc-4a4d-a254-0b091a97e2d9Q61967476-C3FCF73A-89CB-4A30-89E4-98E1A4F9E53BQ62035376-312D027F-EDBF-42E8-AB56-53C03B5C78F2Q62815434-20D9938E-A3E2-4143-954C-2FCF668D7B81Q62822565-5B4C7E5F-D587-4E60-A9C6-D1C233EBE999Q63322392-311AB897-100A-412E-A3E8-699389522427Q63338857-528C8B08-821C-4B16-8C71-43B7F4BEF3B9Q63340127-7D0556B1-043E-426B-9F48-4500A665D484Q63393779-FFA1456B-B069-49A2-ACD0-D9592A2833BEQ63397289-AA3C984C-9FEF-49B2-BC66-2447DF5DC01BQ63401040-A16B2918-2CE3-4236-93A6-7A8F331C2496Q63580423-50035AA6-7151-4789-BB93-A53EF56A2553Q63597075-AC9B85B5-2F1B-4307-AA6A-7843A234F8A0Q63613403-5923F3B2-E7D3-4B87-9377-8DB5B61A5282Q64336949-C99FD6C2-FACB-46E4-87BD-28323ACA0507Q64348732-4BA03969-9F37-47A7-A85E-B85FF12100E1Q65466138-5FCCCE86-5241-4636-91AC-CCA8FEBE3493Q87755922-221fa1d8-45bb-0b5d-a5fc-02c9ff018efbQ90799655-e869a1b6-4b80-dc84-9c6e-f7f0fcb07a9b
P921
description
Anticorpo monoclonale
@it
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tocilizumab
@de
Tocilizumab
@it
Tocilizumab
@nl
Tocilizumab
@sh
Tocilizumab
@tr
Tocilizumab
@vi
Tosilitsumabi
@fi
tocilizumab
@ca
tocilizumab
@en
tocilizumab
@es
type
label
Tocilizumab
@de
Tocilizumab
@it
Tocilizumab
@nl
Tocilizumab
@sh
Tocilizumab
@tr
Tocilizumab
@vi
Tosilitsumabi
@fi
tocilizumab
@ca
tocilizumab
@en
tocilizumab
@es
altLabel
375823-41-9
@fr
Actemra
@es
Actemra
@pt
MRA
@en
R-1569
@en
RG-1569
@en
RHPM-1
@en
Roactemra
@es
Tocilzumab
@es
atlizumab
@ca
prefLabel
Tocilizumab
@de
Tocilizumab
@it
Tocilizumab
@nl
Tocilizumab
@sh
Tocilizumab
@tr
Tocilizumab
@vi
Tosilitsumabi
@fi
tocilizumab
@ca
tocilizumab
@en
tocilizumab
@es
P2175
P31
P268
P269
P592
P6366
P646
P665
P2115
N0000180629
P2175
P2275
tocilizumab
@en
P231
375823-41-9